Figure 4
Trajectories for sacubitril–valsartan dose and Hb patterns, and Kaplan–Meier survival curves for groups in the anemia treatment analysis. For the anemia treatment analysis, we collected data from the EMR for 236 S/V-using patients who had recorded renal function, LVEF, and Hb data at the initiation of S/V therapy (baseline). (A) The numbers within the bars indicate the number of patients receiving each dosage at different time points of the observation period. (B) Using the SAS procedure “PROC TRAJ”, we identified four distinct Hb patterns. (C) Kaplan–Meier survival analyses demonstrated that the patients with “decreasing Hb” had significantly lower survival rates than did those with “stable Hb.” (D) Twelve months after initiating S/V therapy, we grouped the patients by their Hb12M values and whether they had been prescribed anemia treatments such as iron or folate. The patients without anemia treatment prescriptions and with Hb of < 12 g/dL had significantly lower survival rates than those with Hb of ≥ 12 g/dL. However, this trend was not evident among the patients with anemia treatment prescriptions. BUN: blood urea nitrogen; eGFR: estimated glomerular filtration rate; EMR: electronic medical records; Hb: hemoglobin; Hb12M: hemoglobin levels at 12 months after S/V initiation; LVEF: left ventricular ejection fraction; S/V: sacubitril–valsartan.
